Anti-hCD20-Ga-hIgA2 features a human IgA2 constant region (Fc) and the variable region of Obinutuzumab (formerly named Afutuzumab or GA101) which targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes.
Obinutuzumab, is a type II (second generation) non-fucosylated, fully humanized IgG1 monoclonal antibody (mAb) with improved therapeutic efficacy compared with previously developed type I (first generation) anti-hCD20 mAbs, such as Rituximab and Ofatumumab. Obinutuzumab has been approved by the FDA for the treatment of chronic lymphocytic leukaemia (CLL) [1-3].
InvivoGen's Anti-hCD20-Ga-hIgA2 is generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography (peptide M).
More isotypes of this antibody are availbale and can be used for comparison of biological activities such as ADCC (see below).
InvivoGen also provides type I anti-hCD20 mAbs featuring the variable regions of as Rituximab or Ofatumumab, with either native or engineered Fc region.
Read our review on Antibody Isotypes
- Gagez AL. & Cartron G., 2014. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 26(5):484-91.
- Smolej L., 2014. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmgenomics Pers Med. 8:1-7.
- Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.